CLNN News and Press, Clene Inc. From 03/06/23

Significant preservation of function (ALSFRS-R) from randomization to 48 weeks (p=0.0159) Significant preservation of function (ALSFRS-R) during the long-term open-label extension (OLE) week 24 to 120 weeks from randomization (p=0.0057) Significantly reduced risk of ALS ...

Positive clinical results demonstrated in stable relapsing multiple sclerosis patients adjunctive to immunomodulatory disease modifying therapy was previously reported Updated Visual Evoked Potential (VEP) findings provide evidence of improved information sig...

4 Tips for Analyzing Penny Stocks in 2023 Penny stocks can be an attractive option for investors looking to get in on the ground floor of small companies with high growth potential. However, these stocks are typically riskier than more established stocks, and require careful analysis before i...

Clene ( NASDAQ: CLNN ) said new data from a phase 2 trial in multiple sclerosis (MS) showed that CNM-Au8 treatment improved brain neuronal structural integrity. The company reported updated MRI results from the phase 2 trial called VISIONARY-MS, 48-week treatment period in patients wi...

MRI results reinforce the clinical neurological improvements previously reported MRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory effect MRI results consistently favor CNM-Au8 improvement of neuronal integrity an...

SALT LAKE CITY, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company today announced that it will participate in Renmark Financial Commun...

Clene ( NASDAQ: CLNN ) on Tuesday said a phase two study of its zinc and silver solution CNM-ZnAg for the treatment of COVID-19 failed to meet its main goal. The mid-stage trial assessed the efficacy and safety of CNM-ZnAg in COVID infected participants in Brazil. Participants ra...

Primary endpoint of time to substantial symptom resolution was not met in acutely symptomatic, non-hospitalized COVID-19 patients CNM-ZnAg treatment was safe and well-tolerated SALT LAKE CITY, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiari...

SALT LAKE CITY, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease...

CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct to background immunomodulating disease modifying therapies (DMTs) No appr...